Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 42

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1C
Chunk 42
---
 290,196 Contingent consideration, long-term— 1,380 Operating lease liabilities, long-term27,382 33,196 Deferred income tax liabilities, net4,961 24,963 Other liabilities7,600 6,422 Total liabilities332,340 356,157 Commitments and contingencies (Note 16)Stockholders’ equityCommon stock, $0.001 par value; 130,000,000 shares authorized; 55,743,095 and 54,723,356 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively56 55 Additional paid-in capital479,440 439,493 Accumulated other comprehensive loss, net of tax(189)(593)Retained earnings556,426 482,561 Total stockholders’ equity1,035,733 921,516 Total liabilities and stockholders’ equity$1,368,073 $1,277,673 

See accompanying notes.

92

Supernus Pharmaceuticals, Inc.

Consolidated Statements of Earnings

(in thousands, except share and per share data) Year Ended December 31, 202420232022RevenuesNet product sales$637,696 $573,933 $649,432 Royalty, licensing and other revenues24,121 33,588 17,806 Total revenues661,817 607,521 667,238 Costs and expensesCost of goods sold(a)77,906 83,779 87,221 Research and development108,796 91,593 74,552 Selling, general and administrative321,582 336,361 377,221 Amortization of intangible assets77,977 82,385 82,630 Intangible asset impairment charges— 20,189 — Contingent consideration gain(6,110)(1,517)(510)Total costs and expenses580,151 612,790 621,114 Operating earnings (loss)81,666 (5,269)46,124 Other income (expense)Interest and other income, net16,204 10,453 21,689 Interest expense— (2,415)(7,070)Total other income (expense), net16,204 8,038 14,619 Earnings before income taxes97,870